Related Experiment Video
Updated: Feb 14, 2026

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth
Published on: August 11, 2011
STAT3/p53 pathway activation disrupts IFN-β-induced dormancy in tumor-repopulating cells
Yuying Liu1,2, Jiadi Lv1, Jinyan Liu1
1National Key Laboratory of Medical Molecular Biology and Department of Immunology, Institute of Basic Medical Sciences, and.
Abstract:
Dynamic interaction with the immune system profoundly regulates tumor cell dormancy. However, it is unclear how immunological cues trigger cancer cell-intrinsic signaling pathways for entering into dormancy. Here, we show that IFN-β treatment induced tumor-repopulating cells (TRC) to enter dormancy through an indolamine 2,3-dioxygenase/kynurenine/aryl hydrocarbon receptor/p27-dependent (IDO/Kyn/AhR/p27-dependent) pathway. Strategies to block this metabolic circuitry did not relieve dormancy, but led to apoptosis of dormant TRCs in murine and human melanoma models. Specifically, blocking AhR redirected IFN-β signaling to STAT3 phosphorylation through both tyrosine and serine sites, which subsequently facilitated STAT3 nuclear translocation and subsequent binding to the p53 promoter in the nucleus. Upregulation of p53 in turn disrupted the pentose phosphate pathway, leading to excessive ROS production and dormant TRC death. Additionally, in melanoma patients, high expression of IFN-β correlated with tumor cell dormancy. Identification of this mechanism for controlling TRC dormancy by IFN-β provides deeper insights into cancer-immune interaction and potential new cancer immunotherapeutic modalities.
Related Concept Videos
TGF - β Signaling Pathway
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Induced Pluripotent Stem Cells
Other Glycolytic Pathways
Respiration Pathways
Auditory Pathway
When viewed cross-sectionally, the cochlea reveals the scala vestibuli and scala tympani flanking...

